文献速递血栓与止血

单剂量利妥昔单抗联合糖皮质激素对比环磷酰胺联合糖皮质激素治疗新诊断获得性血友病A患者:一项多中心、开放标签、随机非劣效性试验

Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial.
PubMed 文献 · Am J Hematol · 2023-10-18

该多中心随机非劣效性试验纳入63例新诊断获得性血友病A患者,1:1随机接受糖皮质激素联合单剂量利妥昔单抗或联合环磷酰胺。利妥昔单抗组8周内完全缓解率为77.4%,环磷酰胺组为68.8%,绝对差-8.67%(95%CI下限-13.11%),达到非劣效性(P=0.005)。两组治疗相关不良事件发生率无差异。

要点

  • 利妥昔单抗组完全缓解24/31(77.4%),环磷酰胺组22/32(68.8%),绝对差-8.67%(95%CI下限-13.11%),非劣效性P=0.005。
  • 两组治疗相关不良事件发生率无差异。
  • 作者认为单剂量利妥昔单抗联合糖皮质激素方案可能被推荐为AHA一线治疗,尤其在中国AHA患者呈年轻化趋势的情况下。

核心结论

  • 单剂量利妥昔单抗联合糖皮质激素方案在8周内完全缓解率方面非劣效于环磷酰胺联合糖皮质激素方案,且治疗相关不良事件发生率无差异。
  • 作者认为该方案可能被推荐作为获得性血友病A的一线治疗,尤其在中国AHA患者呈年轻化趋势的情况下。

研究设计与样本

  • 多中心、开放标签、随机非劣效性试验,2017年至2022年从五个中心纳入63例新诊断获得性血友病A患者,1:1随机分组。
  • 利妥昔单抗组31例接受糖皮质激素(甲泼尼龙0.8 mg/kg每日,前3周,之后逐渐减量)联合单剂量利妥昔单抗375 mg/m2。
  • 环磷酰胺组32例接受糖皮质激素(甲泼尼龙0.8 mg/kg每日,前3周,之后逐渐减量)联合环磷酰胺2 mg/kg每日,直至抑制物转阴,最长5周。
  • 主要结局为8周内完全缓解率,完全缓解定义为FVIII活性≥50 IU/dL、FVIII抑制物检测不到、免疫抑制治疗减量且24小时无出血且未使用旁路制剂。
  • 非劣效界值为绝对差异20%。

主要发现

  • 利妥昔单抗组24例(77.4%)达到完全缓解,环磷酰胺组22例(68.8%)达到完全缓解,绝对差-8.67%(95%CI下限-13.11%),非劣效性P=0.005。
  • 两组治疗相关不良事件发生率无差异。
  • 单剂量利妥昔单抗联合糖皮质激素方案显示出相似疗效和安全性,未报告环磷酰胺所见的继发性恶性肿瘤或生殖毒性风险。

关键数值与推荐

  • 完全缓解定义:FVIII活性≥50 IU/dL、FVIII抑制物检测不到、免疫抑制治疗减量且24小时无出血且未使用旁路制剂。
  • 非劣效界值为绝对差异20%。
  • 利妥昔单抗组完全缓解率77.4%(24/31) vs 环磷酰胺组68.8%(22/32),绝对差-8.67%(95%CI下限-13.11%),非劣效性P=0.005。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired hemophilia A (AHA) is a rare but serious bleeding disorder. Randomized controlled trial (RCT) comparing the efficacy of immunosuppression therapy for AHA lacks. We conducted the first multicenter RCT aiming to establish whether the single-dose rituximab combination regimen was noninferior to the cyclophosphamide combination regimen. From 2017 to 2022, 63 patients with newly diagnosed AHA from five centers were randomly assigned 1:1 to receive glucocorticoid (methylprednisolone 0.8 mg/kg per day for the first 3 weeks and then tapered) plus single-dose rituximab (375 mg/m2 ; n = 31) or plus cyclophosphamide (2 mg/kg per day until inhibitor becomes negative, for a maximum of 5 weeks; n = 32). The primary outcome was complete remission (CR, defined as FVIII activity ≥50 IU/dL, FVIII inhibitor undetectable, immunosuppression tapered and no bleeding for 24 h without bypassing agents) rate measured within 8 weeks. The noninferiority margin was an absolute difference of 20%. Twenty-four (77.4%) patients in the rituximab group and 22 (68.8%) patients in the cyclophosphamide group achieved CR, which showed the noninferiority of the single-dose rituximab-based regimen (absolute difference = -8.67%, lower limit of the 95% confidence interval = -13.11%; Pnoninferiority = 0.005). No difference was found in the incidence of treatment-related adverse events. Single-dose rituximab plus glucocorticoid regimen showed similar efficacy and safety, without a reported risk of secondary malignancies or reproductive toxicity seen in cyclophosphamide, it might be recommended as a first-line therapy for AHA, especially in China where there is a young age trend in AHA patients. This trial was registered at ClinicalTrials.gov as #NCT03384277.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Wang P, Zhou R, Xue F, et al. Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial. Am J Hematol. 2023. PMID: 37851608. doi:10.1002/ajh.27128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。